Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | GLRA1 | P23415 | 2/20 | 0.31 |
| ▸ | GLRB | P48167 | 2/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
| ▸ | TAS2R46 | P59540 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
| ▸ | TAS2R10 | Q9NYW0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisnordihydrotoxiferine SCHEMBL29525342 | 0.86 | CHRNA7 (0.56) | CHRNA7HTR3ACHRM2CHRNA4KCNH2 | |
| Isostrychnine SCHEMBL29898321 | 0.60 | CHRNA7 (0.43) | CHRNA7HTR3ACHRM2CHRNA4KCNH2 | |
| Hydrochloric Acid SCHEMBL31650965 | 0.57 | CHRNA7 (1.00) | CHRNA7HTR3ACHRM2CHRNA4KCNH2 | |
| Vinervine SCHEMBL30046744 | 0.57 | MEN1 (0.74) | MEN1KMT2ATDP1OPRM1OPRK1 | |
| SCHEMBL31150554 | 0.53 | MEN1 (1.00) | MEN1KMT2ATDP1OPRM1OPRK1 | |
| Alcuronium SCHEMBL30817419 | 0.53 | CHRNA7 (0.98) | CHRNA7HTR3ACHRM2CHRNA4KCNH2 | |
| Akuammicine SCHEMBL29517606 | 0.53 | MEN1 (0.69) | MEN1KMT2ATDP1OPRM1OPRK1 | |
| SCHEMBL29779952 | 0.45 | BCHE (0.48) | MEN1KMT2ACYP3A4 | |
| SCHEMBL27972933 | 0.45 | BCHE (0.48) | MEN1KMT2ACYP3A4 | |
| SCHEMBL4981374 | 0.43 | OPRL1 (0.55) | OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122012425-A | Steroid 11 alpha-hydroxylase and use thereof | 沈阳博泰生物制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| WO-2025203035-A1 | AN IMPROVED PROCESS FOR PREPARATION OF 25-OH PROVITAMIN D3(CALCIFEDIOL) | FERMENTA BIOTECH LIMITED (IN) | 2025-10-02 | — | — | WO | claimed |
| US-20250145659-A1 | SYNTHESIS OF CHOLESTEROL FORM BISNORALCOHOL | FERMENTA BIOTECH LIMITED (IN) | 2025-05-08 | — | — | US | claimed |
| CN-119930727-A | Double-alcohol-reduction extraction and purification method | 云南泽维制药有限公司 | 2025-05-06 | — | — | CN | claimed |
| EP-4539853-A1 | HUMORAL IMMUNE ACTIVATORS FOR THE TREATMENT OF HUMORAL IMMUNOSUPPRESSED PATHOLOGIES, CANCER AND INFECTIOUS DISEASE AND HUMORAL IMMUNE SUPPRESSORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Navrogen, Inc. (US) | 2025-04-23 | — | — | EP | claimed |
| CN-119677519-A | Humoral immune activators for the treatment of humoral immune-suppressive pathologies, cancers and infectious diseases and humoral immune inhibitors for the treatment of inflammatory diseases | 纳夫罗根公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119462808-A | Preparation method of 1 alpha-hydroxy bisnoralcohol | 浙江工业大学 | 2025-02-18 | — | — | CN | claimed |
| CN-119234039-A | Engineered microorganisms for fermentative production of progesterone and ursodeoxycholic acid | 杭州恩和生物科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4452409-A1 | SYNTHESIS OF CHOLESTEROL FORM BISNORALCOHOL | Fermenta Biotech Limited (IN) | 2024-10-30 | — | — | EP | claimed |
| CN-118666927-A | Di-noralcohol derivative and preparation method and application thereof | 华东师范大学 | 2024-09-20 | — | — | CN | claimed |
| CN-118652860-A | Alpha-ketoglutarate dependent dioxygenase mutant and application and engineering bacteria thereof | 武汉艾默佳华生物科技有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-117801044-B | Continuous production method and device for progesterone | 天津凯莱英医药科技发展有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-113880904-B | New method and compounds for synthesizing dydrogesterone | 苏州朗科生物技术股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117801044-A | Continuous production method and device for progesterone | 天津凯莱英医药科技发展有限公司 | 2024-04-02 | — | — | CN | claimed |
| WO-2023245086-A1 | HUMORAL IMMUNE ACTIVATORS FOR THE TREATMENT OF HUMORAL IMMUNOSUPPRESSED PATHOLOGIES, CANCER AND INFECTIOUS DISEASE AND HUMORAL IMMUNE SUPPRESSORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Navrogen, Inc. (US) | 2023-12-21 | — | — | WO | claimed |
| CN-115029368-B | Genetically engineered bacterium for producing bisnoralcohol and application thereof | 中国科学院上海高等研究院 | 2023-10-31 | — | — | CN | claimed |
| CN-116925986-A | Genetically engineered bacterium for preparing steroid medicine intermediate androstenedione and bisnoralcohol and method for preparing steroid medicine intermediate androstenedione and bisnoralcohol | 中国科学院上海高等研究院 | 2023-10-24 | — | — | CN | claimed |
| WO-2023152768-A1 | SYNTHESIS OF CHOLESTEROL FORM BISNORALCOHOL | FERMENTA BIOTECH LIMITED (IN) | 2023-08-17 | — | — | WO | claimed |
| CN-121801726-B | Kluyveromyces marxianus genetically engineered bacterium and application thereof | LIXING (TIANJIN) BIOTECHNOLOGY Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-113956317-A | Impurity removal method for progesterone | 浙江神洲药业有限公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145659-A1 | SYNTHESIS OF CHOLESTEROL FORM BISNORALCOHOL | HMGCR, DHCR7, CYP46A1 | CHRNA7 350/4885HTR3A 2563/4885CHRM2 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.